Trade Madrigal Pharmaceuticals, Inc. - MDGL CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.97 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026346% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.004124% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Madrigal Pharmaceuticals Inc ESG Risk Ratings
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
Prev. Close* | 234.91 |
Open* | 236.91 |
1-Year Change* | 226.28% |
Day's Range* | 233.18 - 243.65 |
52 wk Range | 57.21-322.67 |
Average Volume (10 days) | 490.55K |
Average Volume (3 months) | 9.70M |
Market Cap | 3.72B |
P/E Ratio | -100.00K |
Shares Outstanding | 19.74M |
Revenue | N/A |
EPS | -19.24 |
Dividend (Yield %) | N/A |
Beta | -0.50 |
Next Earnings Date | Feb 21, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Dec 5, 2023 | 234.91 | 14.05 | 6.36% | 220.86 | 236.79 | 219.89 |
Dec 4, 2023 | 221.32 | 13.68 | 6.59% | 207.64 | 221.77 | 207.64 |
Dec 1, 2023 | 212.98 | 11.45 | 5.68% | 201.53 | 213.11 | 195.87 |
Nov 30, 2023 | 203.12 | 2.30 | 1.15% | 200.82 | 208.29 | 199.98 |
Nov 29, 2023 | 197.23 | 5.50 | 2.87% | 191.73 | 200.05 | 189.12 |
Nov 28, 2023 | 190.81 | -2.86 | -1.48% | 193.67 | 195.41 | 187.38 |
Nov 27, 2023 | 196.93 | 4.95 | 2.58% | 191.98 | 197.61 | 190.40 |
Nov 24, 2023 | 194.32 | 8.17 | 4.39% | 186.15 | 200.25 | 186.15 |
Nov 22, 2023 | 190.09 | -2.15 | -1.12% | 192.24 | 195.94 | 186.13 |
Nov 21, 2023 | 188.22 | 3.45 | 1.87% | 184.77 | 190.55 | 181.60 |
Nov 20, 2023 | 189.71 | 13.81 | 7.85% | 175.90 | 190.52 | 174.89 |
Nov 17, 2023 | 176.53 | 6.64 | 3.91% | 169.89 | 176.68 | 164.94 |
Nov 16, 2023 | 168.50 | 1.61 | 0.96% | 166.89 | 170.48 | 159.89 |
Nov 15, 2023 | 161.55 | 5.65 | 3.62% | 155.90 | 174.79 | 154.91 |
Nov 14, 2023 | 156.37 | 2.91 | 1.90% | 153.46 | 156.62 | 150.24 |
Nov 13, 2023 | 145.91 | 9.99 | 7.35% | 135.92 | 146.69 | 135.01 |
Nov 10, 2023 | 138.51 | 1.60 | 1.17% | 136.91 | 138.82 | 134.81 |
Nov 9, 2023 | 136.25 | -7.16 | -4.99% | 143.41 | 144.17 | 133.73 |
Nov 8, 2023 | 143.21 | -6.69 | -4.46% | 149.90 | 151.57 | 142.06 |
Nov 7, 2023 | 151.92 | 5.02 | 3.42% | 146.90 | 153.90 | 145.46 |
Madrigal Pharmaceuticals, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Wednesday, February 21, 2024 | ||
Time (UTC) 13:30 | Country US
| Event Q4 2023 Madrigal Pharmaceuticals Inc Earnings Release Q4 2023 Madrigal Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Revenue | 0 | 0 | 0 | 0 | 0 |
Total Operating Expense | 293.571 | 242.482 | 206.673 | 94.972 | 40.682 |
Selling/General/Admin. Expenses, Total | 48.13 | 37.318 | 21.864 | 22.648 | 15.293 |
Research & Development | 245.441 | 205.164 | 184.809 | 72.324 | 25.389 |
Operating Income | -293.571 | -242.482 | -206.673 | -94.972 | -40.682 |
Interest Income (Expense), Net Non-Operating | -1.779 | 0.363 | 4.329 | 11.024 | 7.671 |
Net Income Before Taxes | -295.35 | -241.846 | -202.244 | -83.948 | -32.811 |
Net Income After Taxes | -295.35 | -241.846 | -202.244 | -83.948 | -32.811 |
Net Income Before Extra. Items | -295.35 | -241.846 | -202.244 | -83.948 | -32.811 |
Net Income | -295.35 | -241.846 | -202.244 | -83.948 | -32.811 |
Income Available to Common Excl. Extra. Items | -295.35 | -241.846 | -202.244 | -83.948 | -32.811 |
Income Available to Common Incl. Extra. Items | -295.35 | -241.846 | -202.244 | -83.948 | -32.811 |
Diluted Net Income | -295.35 | -241.846 | -202.244 | -83.948 | -32.811 |
Diluted Weighted Average Shares | 17.1372 | 16.5352 | 15.4466 | 15.3947 | 14.7967 |
Diluted EPS Excluding Extraordinary Items | -17.2344 | -14.6261 | -13.0931 | -5.45306 | -2.21745 |
Diluted Normalized EPS | -17.2344 | -14.6261 | -13.0931 | -5.45306 | -2.21745 |
Other, Net | 0 | 0.273 | 0.1 | 0 | 0.2 |
Total Extraordinary Items | 0 | 0 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Revenue | 0 | 0 | 0 | 0 | 0 |
Total Operating Expense | 86.45 | 78.336 | 85.299 | 80.412 | 70.273 |
Selling/General/Admin. Expenses, Total | 17.845 | 16.182 | 14.557 | 12.141 | 11.774 |
Research & Development | 68.605 | 62.154 | 70.742 | 68.271 | 58.499 |
Operating Income | -86.45 | -78.336 | -85.299 | -80.412 | -70.273 |
Interest Income (Expense), Net Non-Operating | 0.65 | 1.44 | -0.606 | -0.785 | -0.457 |
Other, Net | 0 | 0 | 0 | ||
Net Income Before Taxes | -85.8 | -76.896 | -85.905 | -81.197 | -70.73 |
Net Income After Taxes | -85.8 | -76.896 | -85.905 | -81.197 | -70.73 |
Net Income Before Extra. Items | -85.8 | -76.896 | -85.905 | -81.197 | -70.73 |
Net Income | -85.8 | -76.896 | -85.905 | -81.197 | -70.73 |
Income Available to Common Excl. Extra. Items | -85.8 | -76.896 | -85.905 | -81.197 | -70.73 |
Income Available to Common Incl. Extra. Items | -85.8 | -76.896 | -85.905 | -81.197 | -70.73 |
Diluted Net Income | -85.8 | -76.896 | -85.905 | -81.197 | -70.73 |
Diluted Weighted Average Shares | 18.3109 | 18.1879 | 17.2386 | 17.1034 | 17.1034 |
Diluted EPS Excluding Extraordinary Items | -4.68572 | -4.22786 | -4.98329 | -4.74742 | -4.13544 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -4.68572 | -4.22786 | -4.98329 | -4.74742 | -4.13544 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 361.369 | 271.684 | 285.163 | 440.197 | 485.201 |
Cash and Short Term Investments | 358.774 | 270.346 | 284.149 | 439.045 | 483.718 |
Cash & Equivalents | 331.549 | 36.269 | 54.004 | 46.697 | 57.379 |
Short Term Investments | 27.225 | 234.077 | 230.145 | 392.348 | 426.339 |
Total Receivables, Net | |||||
Prepaid Expenses | 2.595 | 1.338 | 1.014 | 1.152 | 1.483 |
Total Assets | 362.572 | 273.332 | 286.995 | 442.056 | 485.428 |
Property/Plant/Equipment, Total - Net | 1.203 | 1.648 | 1.832 | 1.859 | 0.227 |
Total Current Liabilities | 115.894 | 76.838 | 46.557 | 25.13 | 8.444 |
Accounts Payable | 23.831 | 21.38 | 1.017 | 1.178 | 2.487 |
Accrued Expenses | 92.063 | 55.458 | 45.54 | 23.952 | 5.957 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | |||||
Total Liabilities | 165.183 | 77.225 | 47.025 | 25.491 | 8.444 |
Total Long Term Debt | 49.289 | 0 | 0 | 0 | 0 |
Total Equity | 197.389 | 196.107 | 239.97 | 416.565 | 476.984 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.002 | 0.002 | 0.002 | 0.002 | 0.002 |
Additional Paid-In Capital | 1160.08 | 863.495 | 665.385 | 639.567 | 616.573 |
Retained Earnings (Accumulated Deficit) | -962.66 | -667.31 | -425.464 | -223.22 | -139.272 |
Other Equity, Total | -0.032 | -0.08 | 0.047 | 0.216 | -0.319 |
Total Liabilities & Shareholders’ Equity | 362.572 | 273.332 | 286.995 | 442.056 | 485.428 |
Total Common Shares Outstanding | 18.1025 | 17.1034 | 15.5082 | 15.4291 | 15.409 |
Other Liabilities, Total | 0 | 0.387 | 0.468 | 0.361 | |
Long Term Debt | 49.289 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 235.469 | 301.595 | 331.284 | 361.369 | 157.112 |
Cash and Short Term Investments | 232.351 | 298.418 | 329.477 | 358.774 | 153.192 |
Cash & Equivalents | 51.385 | 77.196 | 113.308 | 331.549 | 41.112 |
Short Term Investments | 170.296 | 221.222 | 216.169 | 27.225 | 93.852 |
Prepaid Expenses | 3.118 | 3.177 | 1.807 | 2.595 | 3.92 |
Total Assets | 237.964 | 302.461 | 332.449 | 362.572 | 158.644 |
Property/Plant/Equipment, Total - Net | 2.495 | 0.866 | 1.165 | 1.203 | 1.532 |
Total Current Liabilities | 99.665 | 99.706 | 98.348 | 115.894 | 98.92 |
Accounts Payable | 16.542 | 17.534 | 12.128 | 23.831 | 18.562 |
Accrued Expenses | 83.123 | 82.172 | 86.22 | 92.063 | 80.358 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 215.715 | 198.955 | 182.313 | 165.183 | 147.974 |
Total Long Term Debt | 114.727 | 99.249 | 83.965 | 49.289 | 48.983 |
Other Liabilities, Total | 1.323 | 0 | 0.071 | ||
Total Equity | 22.249 | 103.506 | 150.136 | 197.389 | 10.67 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
Common Stock | 0.002 | 0.002 | 0.002 | 0.002 | 0.002 |
Additional Paid-In Capital | 1246.39 | 1228.95 | 1189.78 | 1160.08 | 887.66 |
Retained Earnings (Accumulated Deficit) | -1224.1 | -1125.36 | -1039.56 | -962.66 | -876.755 |
Other Equity, Total | -0.042 | -0.089 | -0.086 | -0.032 | -0.237 |
Total Liabilities & Shareholders’ Equity | 237.964 | 302.461 | 332.449 | 362.572 | 158.644 |
Total Common Shares Outstanding | 18.4942 | 18.459 | 18.2831 | 18.1025 | 17.1034 |
Cash | 10.67 | 18.228 | |||
Long Term Debt | 114.727 | 99.249 | 83.965 | 49.289 | 48.983 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -295.35 | -241.846 | -202.244 | -83.948 | -32.811 |
Cash From Operating Activities | -224.857 | -183.917 | -157.561 | -41.624 | -25.507 |
Cash From Operating Activities | 0.467 | 0.405 | 0.471 | 0.112 | 0.096 |
Non-Cash Items | 32.422 | 26.873 | 20.73 | 22.759 | 13.489 |
Changes in Working Capital | 37.604 | 30.651 | 23.482 | 19.453 | -6.281 |
Cash From Investing Activities | 206.686 | -5.055 | 159.78 | 30.707 | -380.076 |
Capital Expenditures | -0.217 | -0.209 | -0.334 | -0.172 | -0.022 |
Other Investing Cash Flow Items, Total | 206.903 | -4.846 | 160.114 | 30.879 | -380.054 |
Cash From Financing Activities | 313.451 | 171.237 | 5.088 | 0.235 | 314.335 |
Financing Cash Flow Items | -0.886 | 0 | |||
Issuance (Retirement) of Stock, Net | 264.337 | 171.237 | 5.088 | 0.235 | 314.335 |
Net Change in Cash | 295.28 | -17.735 | 7.307 | -10.682 | -91.248 |
Issuance (Retirement) of Debt, Net | 50 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -76.896 | -295.35 | -209.445 | -128.248 | -57.518 |
Cash From Operating Activities | -84.067 | -224.857 | -166.342 | -107.273 | -49.913 |
Cash From Operating Activities | 0.124 | 0.467 | 0.338 | 0.217 | 0.107 |
Non-Cash Items | 11.683 | 32.422 | 24.034 | 15.599 | 7.477 |
Changes in Working Capital | -18.978 | 37.604 | 18.731 | 5.159 | 0.021 |
Cash From Investing Activities | -186.864 | 206.686 | 140.299 | 75.162 | 55.926 |
Capital Expenditures | -0.035 | -0.217 | -0.188 | -0.155 | -0.052 |
Other Investing Cash Flow Items, Total | -186.829 | 206.903 | 140.487 | 75.317 | 55.978 |
Cash From Financing Activities | 52.69 | 313.451 | 49.114 | 49.114 | 0 |
Issuance (Retirement) of Stock, Net | 17.903 | 264.337 | 0 | 0 | 0 |
Net Change in Cash | -218.241 | 295.28 | 23.071 | 17.003 | 6.013 |
Financing Cash Flow Items | -0.213 | -0.886 | -0.886 | -0.886 | |
Issuance (Retirement) of Debt, Net | 35 | 50 | 50 | 50 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Janus Henderson Investors | Investment Advisor/Hedge Fund | 15.4394 | 3042661 | 1558535 | 2023-09-29 | LOW |
Baker Bros. Advisors LP | Hedge Fund | 7.8404 | 1545113 | 0 | 2023-10-03 | LOW |
Avoro Capital Advisors LLC | Investment Advisor/Hedge Fund | 7.6883 | 1515151 | -151515 | 2023-06-30 | LOW |
Bay City Capital L.L.C. | Venture Capital | 7.6712 | 1511782 | 0 | 2023-03-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 7.4237 | 1462998 | 47070 | 2023-06-30 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 4.7127 | 928734 | 78587 | 2023-06-30 | LOW |
SQN, L.L.C. | Corporation | 3.3264 | 655540 | 0 | 2023-03-31 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 2.7592 | 543759 | 23945 | 2023-06-30 | LOW |
Craves (Frederick B) | Individual Investor | 2.3877 | 470556 | 1198 | 2023-06-15 | LOW |
Assenagon Asset Management S.A. | Investment Advisor | 2.3685 | 466766 | -49822 | 2023-06-30 | HIGH |
Marshall Wace LLP | Investment Advisor/Hedge Fund | 2.3374 | 460644 | -81120 | 2023-06-30 | HIGH |
Taub (Rebecca A) | Individual Investor | 2.2061 | 434758 | -20001 | 2023-03-31 | LOW |
AllianceBernstein L.P. | Investment Advisor/Hedge Fund | 1.8832 | 371116 | 347448 | 2023-06-30 | LOW |
Paulson & Co. Inc. | Hedge Fund | 1.777 | 350200 | 350200 | 2023-06-30 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 1.7704 | 348887 | 86654 | 2023-06-30 | LOW |
OrbiMed Advisors, LLC | Investment Advisor/Hedge Fund | 1.6317 | 321569 | 142579 | 2023-06-30 | LOW |
Perceptive Advisors LLC | Private Equity | 1.5374 | 302987 | -347575 | 2023-06-30 | MED |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.3768 | 271319 | 23262 | 2023-06-30 | LOW |
Artisan Partners Limited Partnership | Investment Advisor | 1.1675 | 230090 | 14320 | 2023-06-30 | LOW |
RTW Investments L.P. | Investment Advisor/Hedge Fund | 1.1243 | 221562 | 221562 | 2023-06-30 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Madrigal Pharmaceuticals, Inc. Company profile
About Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The Company’s lead product candidate, MGL-3196 (resmetirom), is a liver-directed, selective thyroid hormone receptor-ß (THR-ß) agonist for the treatment of non-alcoholic steatohepatitis (NASH)and heterozygous familial hypercholesterolemia (HeFH). Its product pipeline also includes MGL-3745, which is used in the treatment of NASH and HeFH.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Madrigal Pharmaceuticals Inc revenues was not reported. Net loss increased 20% to $241.8M. Higher net loss reflects R & D increase of 11% to $194.5M (expense), G & A increase from $10M to $21.1M (expense), Stock-based Compensation in SGA increase of 36% to $16.2M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$13.09 to -$14.63.
Equity composition
Common Stock $.0001 Par, 10/10, 100M auth., 42,166,779 issd. Insiders control approx. 37.8%. IPO: 2/06/07, 5M shares @ $10 per share by Bear, Stearns & Co. Inc.
Industry: | Bio Therapeutic Drugs |
200 Barr Harbor Dr Ste 400
WEST CONSHOHOCKEN
PENNSYLVANIA 19428-2978
US
Income Statement
- Annual
- Quarterly
News

December RBA preview: no move expected at the final meeting of 2023
The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.
14:47, 4 December 2023
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com